Nivolumab

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Nivolumab and local guidelines before prescribing.

Immune checkpoint inhibitor

Mechanism

PD-1 inhibitor restoring T-cell antitumour activity.

Uses

Melanoma, non-small-cell lung cancer, renal cell carcinoma, Hodgkin lymphoma and other cancers.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Immune-related colitis, pneumonitis, hepatitis, thyroiditis, hypophysitis, rash, fatigue.

Interactions

Immunosuppressants and steroids reduce effect.

Contraindications and cautions

Active autoimmune disease (caution), organ transplant

Monitoring

TFT, LFT, cortisol, glucose, U&E before each cycle

Pregnancy and breastfeeding

Avoid; contraception during and for 5 months after

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive; steroids for immune toxicity

Special advice

Early recognition of immune-related adverse events; steroids for moderate to severe toxicity; carry alert card.

More from the textbook: uses, cautions and other points
Where it is discussed in the book